CAR-T Meeting 2025 | The treatment of acute lymphoblastic leukemia in Brazil
Nelson Hamerschlak, MD, PhD, Albert Einstein Israelite Hospital, São Paulo, Brazil, briefly discusses the treatment of acute lymphoblastic leukemia (ALL) in Brazil, highlighting the country’s established pediatric protocol. For adolescents and young adults, pediatric protocols are also utilized, while older adults are treated with immunotherapy combined with low-dose chemotherapy. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting, held in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
In Brazil, we treat both children and adults with ALL. We have a Brazilian protocol for children for more than 20 years, and these patients have an outcome of surviving with more than 80%. Now we have available bispecific antibodies and other immunotherapies such as inotuzumab and blinatumomab for this kind of patients to get deep remission or to rescue these patients after relapse...
In Brazil, we treat both children and adults with ALL. We have a Brazilian protocol for children for more than 20 years, and these patients have an outcome of surviving with more than 80%. Now we have available bispecific antibodies and other immunotherapies such as inotuzumab and blinatumomab for this kind of patients to get deep remission or to rescue these patients after relapse. Also in adults we treat the adolescents and young people using pediatric-based protocols. And for older people, we prefer to use immunotherapy associated with low doses of chemotherapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Lectures to: Kite, Novartis, Janssen; AB: Pfizer.
